APA

Cutler N. R., Murphy M. F., Nash R. J., Prior P. L. & De Luna D. M. (19900725). Clinical safety, tolerance, and plasma levels of the oral anticholinesterase 1,2,3,4-tetrahydro-9-aminoacridin-1-oL-maleate (HP 029) in Alzheimer's disease: preliminary findings. : Journal of clinical pharmacology.

Chicago

Cutler N R, Murphy M F, Nash R J, Prior P L and De Luna D M. 19900725. Clinical safety, tolerance, and plasma levels of the oral anticholinesterase 1,2,3,4-tetrahydro-9-aminoacridin-1-oL-maleate (HP 029) in Alzheimer's disease: preliminary findings. : Journal of clinical pharmacology.

Harvard

Cutler N. R., Murphy M. F., Nash R. J., Prior P. L. and De Luna D. M. (19900725). Clinical safety, tolerance, and plasma levels of the oral anticholinesterase 1,2,3,4-tetrahydro-9-aminoacridin-1-oL-maleate (HP 029) in Alzheimer's disease: preliminary findings. : Journal of clinical pharmacology.

MLA

Cutler N R, Murphy M F, Nash R J, Prior P L and De Luna D M. Clinical safety, tolerance, and plasma levels of the oral anticholinesterase 1,2,3,4-tetrahydro-9-aminoacridin-1-oL-maleate (HP 029) in Alzheimer's disease: preliminary findings. : Journal of clinical pharmacology. 19900725.